2-imino-6-polyfluoroalkoxybenzothiazole derivatives, and pharmaceutical compositions containing them
Abstract
Compounds of formula: ##STR1## and their salts, in which R 1 represents polyfluoroalkoxy, and R 2 represents alkyl, alkenyl (3-6 C), [cycloalkyl (3-6 C)]-alkyl, carbamoylalkyl, dialkylcarbamoylalkyl, acylaminoalkyl, phenylthioalkyl, hydroxyalkyl, cyanoalkyl, sulphamoylethyl, N-alkylsulphamoylethyl, pyridylthioalkyl, pyridiylalkylthioalkyl, pyridylsulphinylalkyl, alkynyl (3-6 C), phenylsulphinylalkyl, halophenylthioalkyl, (2,2,2-trifluoroethylthio)alkyl, 2-dialkylaminopropyl, pyrimidinylsulphinylalkyl, pyridylalkylsulphinylalkyl, halophenylsulphinylalkyl or (2,2,2-trifluoroethylsulphinyl)alkyl are useful in the treatment of medical conditions associated with the effects of glutamate.
Claims
exact text as granted — not AI-modifiedWe claim:
1. A compound of formula: ##STR9## and its pharmaceutically acceptable salts which are nontoxic, in which R 1 represents polyfluoroalkoxy, and R 2 represents pyridylthioalkyl, pyridylalkylthioalkyl, pyridylsulphinylalkyl, or pyridylalkylsulphinylalkyl, the said slkyl and alkoxy portions containing 1 to 4 carbon atoms each in a straight or branched chain.
2. A compound according to claim 1, in which R 1 represents trifluoromethoxy, pentafluoroethoxy, 2,2,2-trifluoroethoxy, 1,1,2,2-tetrafluoroethoxy or 2,2,3,3,3-pentafluoropropoxy.
3. A pharmaceutical composition which comprises, as active principle, at least one compound according to claim 1, or a salt of such a compound with an inorganic or organic acid, and a compatible pharmaceutically acceptable carrier.
4. A method for the treatment of a medical condition associated with the effects of glutamate which comprises administering to a subject in need of such treatment an amount of a compound according to claim 1, or salt thereof sufficient to inhibit such effects at least partially.
5. A compound as claimed in claim 1 which is 2-imino-3-6-trifluoromethoxybenzothiazoline or its addition salts.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.